Cellular Therapy May Be Viable Option for Advanced Melanoma Patients

Nearly one-third of patients respond to a single infusion of tumor infiltrating lymphocytes

Infiltrating and Destroying Solid Tumors

Engineering a patient’s immune cells to attack cancer offers new hope for solid tumor patients

Expanding Targets for Cell Therapy

Thanks to the infrastructure in place for blood cancers, Moffitt is ready to expand CAR T-cell therapy to solid tumors

Prevention, Screening and Treatment Critical to Reducing Cancer Deaths

Moffitt Cancer Center experts share latest advances at Research Innovations event in New York

Moffitt Cancer Center’s Clinical Trials Focus on Expansion, Diversity and Innovation

The cancer center offers one of the largest portfolios of clinical trials in the nation, with nearly 400 active treatment trials

Moffitt’s Newest Partnership to Advance Cell Therapies for Solid Tumors

Strategic alliance with Turnstone Biologics Corp. focuses on tumor infiltrating lymphocyte therapies

TIL Therapy Shows Promise in Non-Small Cell Lung Cancer

Cellular therapy gave scuba diver Deborah Barker a new option for beating the disease

Can mRNA Vaccines Boost Effectiveness of CAR T-Cell Therapy?

Early trial results show response in solid tumors

Moffitt Study Shows Benefit to Giving CAR T-cell Therapy to Patients Sooner

Using cell therapy as a second-line treatment provided better outcomes for lymphoma patients compared to standard of care

Expanded TIL Therapy Shows Promise for Sarcoma Patients

Moffitt studying whether AYA population will tolerate the therapy well

Can Tumor Mutations Cause Resistance to Cellular Immunotherapy?

Moffitt study shows certain alterations can indicate poor outcomes for lymphoma patients receiving CAR T-cell therapy

5 Questions on a New Treatment for Acute Lymphoblastic Leukemia

‘Off the Shelf’ CAR T Shows Promise

New study results find the therapy is effective for certain lymphoma patients

Moffitt Celebrates Cell Therapy Milestone

The cancer center infused its 500th patient with CAR T-cell therapy

FDA Approves CAR T to Help Patients with Relapsed Multiple Myeloma

For one patient, the therapy, made available to him through a clinical trial, was his last resort

Rethinking Cellular Immunotherapy

Moffitt study uses CAR T therapy to treat side effects of cancer therapy

Accidental Discovery Could Lead to Future Cancer Therapy

Researchers in Europe discover T cell that may help detect and kill several cancers

Bridging Therapy Not Recommended for All CAR T Patients

New data presented by Moffitt shows poorer outcome for patients who receive bridging therapy prior to CAR T-cell therapy.

Third Grade Friends Hold Bake Sale to Raise Money for Cancer Research

The two students mailed a handwritten note to Dr. Frederick Locke, the CAR T investigator at Moffitt, to "use the money we made at our bake sale to he ...

The ReMissions Shine Light on Moffitt’s Mission

“We listen to each other, work together and make harmony together.”